| Anthony Michaelis, | |
|
4300 Marketpointe Dr Ste 100, Bloomington, MN 55435-5435 | |
| (952) 835-9880 | |
| (952) 857-1554 |
| Full Name | Anthony Michaelis |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 7 Years |
| Location | 4300 Marketpointe Dr Ste 100, Bloomington, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992244396 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Cloud Hospital | Saint cloud, MN | Hospital |
| Carris Health Llc | Willmar, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Physicians Professional Association | 9537072657 | 205 |
News Archive
According to researchers at McMaster University, exposure of the fetus to nicotine results in the inability to respond to decreases in oxygen - known as hypoxia - which may result in a higher incidence of SIDS.
Pioneering research by scientists at the Universities of Oxford and Birmingham published today in Nature brings us a step closer to developing targeted therapies for inflammatory diseases.
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.
Researchers from MIT, Alnylam Pharmaceuticals and other institutions have demonstrated the safety of a promising type of genetic therapy that could lead to treatments for a wide range of diseases such as cancer.
› Verified 2 days ago
| Entity Name | Emergency Physicians Professional Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801871934 PECOS PAC ID: 9537072657 Enrollment ID: O20031106000068 |
News Archive
According to researchers at McMaster University, exposure of the fetus to nicotine results in the inability to respond to decreases in oxygen - known as hypoxia - which may result in a higher incidence of SIDS.
Pioneering research by scientists at the Universities of Oxford and Birmingham published today in Nature brings us a step closer to developing targeted therapies for inflammatory diseases.
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.
Researchers from MIT, Alnylam Pharmaceuticals and other institutions have demonstrated the safety of a promising type of genetic therapy that could lead to treatments for a wide range of diseases such as cancer.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anthony Michaelis, 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435-5435 Ph: (952) 835-9880 | Anthony Michaelis, 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435-5435 Ph: (952) 835-9880 |
News Archive
According to researchers at McMaster University, exposure of the fetus to nicotine results in the inability to respond to decreases in oxygen - known as hypoxia - which may result in a higher incidence of SIDS.
Pioneering research by scientists at the Universities of Oxford and Birmingham published today in Nature brings us a step closer to developing targeted therapies for inflammatory diseases.
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.
Researchers from MIT, Alnylam Pharmaceuticals and other institutions have demonstrated the safety of a promising type of genetic therapy that could lead to treatments for a wide range of diseases such as cancer.
› Verified 2 days ago
Rebecca Lynn Meyer, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 | |
Dr. Holly Lynn Schrupp Berg, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 Fax: 952-857-1554 | |
Andrew H Bauer, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 Fax: 952-857-1554 | |
Laura Kuhlman, Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 | |
Elisabeth Marycke Vreede Greenberg, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 Fax: 952-857-1554 | |
Leonardo A Saavedra, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 Fax: 952-857-1554 | |
Dr. Ferris Yeh, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4300 Marketpointe Dr Ste 100, Bloomington, MN 55435 Phone: 952-835-9880 Fax: 952-857-1554 |